GlassScriptPhysician profile
Sunil T Joseph
NPI 1982716098
$5,717.12
in general payments reported to CMS, 2019-2025
36 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $149 · 2021: $380 · 2022: $1,060 · 2023: $865 · 2024: $1,094 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,504.48 | 2019-2025 | |
| Janssen Biotech, INC. | $723.07 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $567.70 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $516.16 | 2019-2024 | |
| Pfizer INC. | $260.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $233.95 | 2019-2022 | |
| Genzyme Corporation | $166.11 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.31 | 2020-2025 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $131.68 | 2019-2025 | Linzess |
| Braintree Laboratories, INC. | $124.19 | 2019-2022 | |
| Medical Device Business Services, INC. | $107.11 | 2019 | |
| Boston Scientific Corporation | $106.31 | 2019 | |
| Intercept Pharmaceuticals, INC. | $99.68 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $94.31 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $87.40 | 2019-2024 | Sucraid, Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $84.57 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $79.04 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $78.56 | 2019-2024 | Dificid |
| Allergan, INC. | $75.15 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $73.65 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $70.13 | 2022-2024 | Dupixent |
| Celltrion USA INC. | $59.53 | 2024-2025 | Vegzelma |
| Ucb, INC. | $52.62 | 2019-2020 | |
| Celgene Corporation | $50.67 | 2023-2024 | Zeposia |
| Vivus LLC | $43.53 | 2019-2024 | Pancreaze |
| Exact Sciences Corporation | $32.60 | 2023-2025 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $21.37 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $20.79 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $20.75 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.87 | 2023 | Rebyota |
| Novo Nordisk INC | $18.52 | 2025 | Wegovy |
| Biocon Biologics INC | $17.36 | 2025 | Yesintek |
| W. L. Gore & Associates, INC. | $15.42 | 2023 | Gore Cardioform Septal Occluder |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2022 | |
| Shionogi INC | $12.32 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,348.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.